Core Viewpoint - Clearmind Medicine Inc. has filed a new international patent application for a combination therapy aimed at addressing obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) [1][2][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to tackle significant health issues, including alcohol use disorder [4] - The company currently holds a portfolio of nineteen patent families, which includes 31 granted patents, and plans to seek additional patents as necessary [5] Health Challenges Addressed - The proprietary combination therapy targets obesity, which affects over 890 million people globally, and MASLD, impacting more than 30% of the adult population [2] - The treatment options for these conditions remain limited despite their widespread prevalence [2] Therapeutic Approach - The combination therapy utilizes MEAI (5-methoxy-2-aminoindane) and Palmitoylethanolamide (PEA), leveraging MEAI's pharmacological profile and PEA's anti-inflammatory and neuroprotective properties [3] - The company believes this novel approach could provide a safe and effective therapeutic alternative for patients [3] Collaboration - The patent filing is part of an ongoing collaboration with SciSparc Ltd., which is also focused on developing therapies for central nervous system disorders [3]